Hrak Chemchirian, MD
Clinical Cardiac Electrophysiology · New Albany, INNPI 1215190988
Payments from drug & device makers
What this record shows
It is spread thinly across 33 manufacturers, the largest accounting for just 20.1%. Reporting peaked in 2022 at $5,451 and has fallen 79.5% since, to $1,117 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in IN, where the typical reported total is $13,586.
Across 200 payments — averaging $61.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$2K
- Biotronik Inc.$2K
- Medical Device Business Services, Inc.$1K
- Biosense Webster, Inc.$1K
- Philips North America LLC$854
- plus $2K from 27 others
What the payments were for
- Travel & lodging$6,22151%
- Food & beverage$6,08449%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $2,477 |
| Boston Scientific | 23 | $2,435 |
| Biotronik Inc. | 4 | $1,668 |
| Medical Device Business Services, Inc. | 5 | $1,252 |
| Biosense Webster, Inc. | 10 | $1,129 |
| Philips North America LLC | 14 | $854 |
| Abbott | 5 | $287 |
| Novartis | 15 | $285 |
| Johnson & Johnson(2 entities) | 15 | $277 |
| Pfizer | 14 | $242 |
| E.r. Squibb & Sons, L.L.C. | 11 | $196 |
| Merck | 10 | $178 |
| Cvrx, Inc. | 1 | $145 |
| Amgen | 7 | $124 |
| Novo Nordisk | 4 | $97 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Acist Medical Systems, Inc. | 3 | $65 |
| Boehringer Ingelheim | 4 | $64 |
| AstraZeneca | 4 | $57 |
| Cardiva Medical, Inc. | 3 | $56 |
| Chiesi USA, Inc. | 3 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Abiomed | 2 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $37 |
| Atricure, Inc. | 1 | $32 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $25 |
| Heartflow, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Altathera Pharmaceuticals LLC | 1 | $14 |
| Bayer | 1 | $13 |
| Thrombolex, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$2,314
- Solia$1,129
- Acticor 7 VR-T DX$1,129
- Edora 8 DR-T$1,129
- BioMonitor$1,129
- Rivacor 7 DR-T$1,129
- GENERAL - THERAPIES$1,107
- Micra$614
- (9124) LM Undivided$419
- LUX-Dx Insertable Cardiac Monitor$149
- Barostim Neo System$145
- SQ RX PULSE GENERATOR$127
- (9520) IGT Devices Undivided$125
- MitraClip$120
- S ICD$108
How this compares
$12,305 in reported general payments places this provider in the 45th percentile of 72 clinical cardiac electrophysiology providers in Indiana.
See all clinical cardiac electrophysiology providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 208 | $210,632 |
| XareltoRivaroxaban | 113 | $138,506 |
| EntrestoSacubitril/Valsartan | 12 | $24,740 |
| MultaqDronedarone Hcl | 24 | $23,231 |
| Dofetilide | 66 | $13,803 |
| Flecainide Acetate | 177 | $8,009 |
| Amiodarone Hcl | 132 | $2,650 |
| Ranolazine ErRanolazine | 41 | $2,601 |
| Midodrine Hcl | 12 | $2,243 |
| Mexiletine Hcl | 31 | $1,655 |
| Sotalol AfSotalol Hcl | 63 | $1,530 |
| Metoprolol Succinate | 183 | $1,439 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 53 | $1,190 |
| ClopidogrelClopidogrel Bisulfate | 106 | $999 |
| SotalolSotalol Hcl | 56 | $734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $242 | $210,632208 claims |
| Johnson & JohnsonXarelto | $277 | $138,506113 claims |
| NovartisEntresto | $285 | $24,74012 claims |
| Sanofi-aventis U.S. LLCMultaq | $66 | $23,23124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 72 clinical cardiac electrophysiology providers in Indiana.
Other clinical cardiac electrophysiology in New Albany
- Eric PrystowskyIndianapolis$1.1M
- Chad BonhommeWestfield$925K
- Kevin TrulockIndianapolis$402K
- Sharath VipparthyIndianapolis$114K
- Jasen GilgeIndianapolis$93K
- Vincent KeatingIndianapolis$80K
- Christopher ReedIndianapolis$80K
- Marcelle StuckyIndianapolis$76K
- Joseph SzwedIndianapolis$67K
- Krishna MalineniIndianapolis$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.